Long-acting injectable HIV treatment leads to rectal shedding in a small proportion of patients with HIV, independent of the oral lead-in phase.

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

The National Institutes of Health’s sweeping cuts of grants that fund scientific research are inflicting pain almost ...

A mathematical modeling study coordinated by UMC Utrecht has shown that sustained HIV remission (without rebound) or HIV ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

Data from the last five years show that many people who contracted HIV had seen a provider in the year before.

Amanda Bleichrodt, MPH, discusses her team’s findings that the US is unlikely to reach the Ending the HIV Epidemic goal of a 90% drop in HIV incidence by 2030.

SPRINGFIELD The Illinois Department of Public Health (IDPH) has issued a standing order that will allow Illinoisans to obtain ...

Problematic substance use leads to relational difficulties, mental health issues, and addiction, which, in the worst cases, ...

One of the House's foremost experts on the nation's health systems breaks down the terrifying pace at which Kennedy is ...